

10/528771

2100 Pennsylvania Avenue, NW  
Washington, DC 20037-3213

T 202.293.7060

F 202.293.7860

401 Castro Street  
Mountain View, CA 94041-2007

T 650.625.8100

F 650.625.8110

AIG Bldg. 14F

1-1-3 Marunouchi

Chiyoda-ku Tokyo 100-0005

Japan

T 03.5220.0200

F 03.5220.0222

www.sughrue.com



SUGHRUE MION, PLLC

Susan J. Mack

T (202) 663-7943

smack@sughrue.com

March 23, 2005

**MAIL STOP PCT**

Commissioner for Patents

P.O. BOX 1450

Alexandria, VA 22313-1450

PCT/JP03/12362

-filed September 26, 2003

Re: Application of Ikuya SEKI, Takayoshi KAWAGUCHI and Yoshifumi SHIRAKAMI  
COMPOUND BINDING TO LEUKOCYTES AND MEDICINAL COMPOSITION CONTAINING THE COMPOUND IN LABELED STATE AS THE ACTIVE INGREDIENT  
Assignee: **NIHON MEDI-PHYSICS CO., LTD.**  
Our Ref: Q86824

Dear Sir:

The following documents and fees are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. §371 and in accordance with the Patent Cooperation Treaty:

- ☒ a copy of the executed Declaration and Power of Attorney.
- ☒ an English translation of the International Application.
- ☒ 21 sheets of drawings.
- ☒ A Statement to Support Filing Sequence Listing, 4 pages of sequence listing and computer readable form of sequence listing
- ☒ a copy of the executed Assignment and PTO 1595 form.
- ☒ a copy of the ISR.
- ☒ a PTO/SB/08 A & B (modified) listing the ISR/IPER references.
- ☒ Notification Concerning Transmittal of Priority Document.
- ☒ a Preliminary Amendment.
- ☒ **it is expressly requested that the national stage of processing be commenced immediately in accordance with 35 U.S.C. § 371(f)**

In addition to the documents submitted herewith, it is assumed that copies of the International Application, the International Search Report and cited references, the International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by §371(c) will be supplied directly by the International Bureau, but if further copies are needed, the undersigned will undertake to provide them upon request.



National Stage Application of  
PCT/JP03/12362  
-filed September 26, 2003

Q86824

The Government filing fee is calculated as follows:

Total claims	<u>10</u>	-	20	=		x	\$50.00	=	<u>\$0.00</u>
Independent claims	<u>1</u>	-	3	=		x	\$200.00	=	<u>\$0.00</u>
Base Fee									<u>\$300.00</u>
Search Fee*									<u>\$400.00</u>
Examination Fee*									<u>\$200.00</u>
Excess Application Pages									<u>\$250.00</u>
<b>TOTAL FILING FEE</b>									<u><b>\$1150.00</b></u>
<b>Recordation of Assignment</b>									<u><b>\$ 40.00</b></u>
<b><u>TOTAL FEE</u></b>									<u><b>\$1190.00</b></u>

\* The international search fee for all claims was not paid to the USPTO, as the ISA, but the ISR is being submitted herewith.

Checks for the statutory filing fee of \$1150.00 and Assignment recordation fee of \$40.00 are attached. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this transmittal letter is attached.


Priority is claimed from:

<u>Country</u>	<u>Application No</u>	<u>Filing Date</u>
Japan	2002-282229	September 27, 2002

Respectfully submitted,

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Susan J. Mack  
Registration No. 30,951



Date: March 23, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q86824

Ikuya SEKI, et al.

Confirmation No.: Unassigned

Appln. No.: Unassigned  
(371 of PCT/JP03/12362)

Group Art Unit: Unassigned

Filed: March 23, 2005

Examiner: Unassigned

For: COMPOUND BINDING TO LEUKOCYTES AND MEDICINAL COMPOSITION  
CONTAINING THE COMPOUND IN LABELED STATE AS THE ACTIVE  
INGREDIENT

STATEMENT TO SUPPORT FILING AND SUBMISSION  
IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

MAIL STOP SEQUENCE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the contents of the 9-page Sequence Listing being filed with the present application, and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same; and
2. all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,



Drew Hissong  
Registration No. 44,765

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 23, 2005